PVC Adverse Event Reporting & Case Management 2 — Questions and Answers
Question 1: Which of the following best defines a 'serious adverse event' (SAE) under ICH E2A guidelines?
- Any adverse event that causes patient discomfort lasting more than 24 hours
- An event resulting in death, life-threatening situation, hospitalization, disability, or congenital anomaly (Correct answer)
- An adverse event that requires a dose reduction of the investigational product
- Any unexpected adverse event not listed in the investigator's brochure
Correct answer: An event resulting in death, life-threatening situation, hospitalization, disability, or congenital anomaly
ICH E2A defines an SAE as one resulting in death, life-threatening risk, inpatient hospitalization, persistent disability, congenital anomaly, or a medically important event.
Question 2: A patient in a clinical trial experiences a hospitalization due to an elective cosmetic procedure. How should this be classified?
- Serious adverse event, because any hospitalization qualifies
- Non-serious adverse event, because elective procedures are excluded from SAE criteria (Correct answer)
- Serious adverse event requiring expedited reporting within 7 days
- Non-serious adverse event that still requires submission in a CIOMS I form
Correct answer: Non-serious adverse event, because elective procedures are excluded from SAE criteria
Elective hospitalizations that were pre-planned and not caused by the investigational product are excluded from SAE seriousness criteria.
Question 3: Under 21 CFR 312.32, what is the expedited reporting timeframe for an unexpected fatal or life-threatening SUSAR in a US IND?
- 7 calendar days for fatal/life-threatening, 15 calendar days for other unexpected serious events (Correct answer)
- 15 calendar days for all unexpected serious adverse events
- 7 business days for fatal events only
- 24 hours for fatal events and 72 hours for life-threatening events
Correct answer: 7 calendar days for fatal/life-threatening, 15 calendar days for other unexpected serious events
FDA requires 7-calendar-day reports for fatal or life-threatening unexpected SUSARs and 15-calendar-day reports for other unexpected serious adverse drug reactions.
Question 4: What is the primary purpose of the MedWatch 3500A form in the US post-marketing pharmacovigilance system?
- To report adverse events from clinical trials to the FDA
- To submit mandatory expedited adverse event reports to FDA for marketed products (Correct answer)
- To document internal quality deviations related to product complaints
- To notify the IRB of serious adverse events during post-approval studies
Correct answer: To submit mandatory expedited adverse event reports to FDA for marketed products
The MedWatch 3500A (mandatory reporting form) is used by manufacturers, importers, and distributors to submit required expedited safety reports to FDA for marketed products.
Question 5: In pharmacovigilance case processing, what does 'case narrative' refer to?
- The regulatory agency's formal response to a safety report
- A concise medical summary of all relevant information in an individual case safety report (Correct answer)
- The statistical analysis plan for aggregate adverse event data
- The patient's own written account of their adverse event experience
Correct answer: A concise medical summary of all relevant information in an individual case safety report
A case narrative is a concise, chronological medical summary that synthesizes all relevant information from an ICSR into a coherent clinical account.
Question 6: Which regulatory database is used to submit Individual Case Safety Reports (ICSRs) to the FDA for marketed products?
- EudraVigilance
- FDA Adverse Event Reporting System (FAERS) (Correct answer)
- VigiBase
- MedDRA
Correct answer: FDA Adverse Event Reporting System (FAERS)
FAERS (FDA Adverse Event Reporting System) is the FDA's database that receives and manages ICSRs for marketed products in the US.
Question 7: When a spontaneous adverse event report is received with incomplete patient information, what is the minimum dataset required to make it a valid case for submission?
- An identifiable patient, an identifiable reporter, a suspect product, and at least one adverse event (Correct answer)
- Patient name, date of birth, full medical history, and complete contact information
- Patient initials, suspect product batch number, and prescribing physician name
- Confirmed diagnosis, hospitalization record, and causality assessment by a physician
Correct answer: An identifiable patient, an identifiable reporter, a suspect product, and at least one adverse event
The four minimum criteria for a valid ICSR are: an identifiable patient, an identifiable reporter, at least one suspect medicinal product, and at least one adverse event.
PVC Adverse Event Reporting & Case Management 2
Which of the following best defines a 'serious adverse event' (SAE) under ICH E2A guidelines?